来那度胺难治性多发性骨髓瘤:临床试验与真实世界证据的系统性文献综述
该系统性文献综述检索2008年1月至2023年10月的临床试验与真实世界研究,评估既往接受≥1线治疗且来那度胺难治的复发/难治多发性骨髓瘤成人患者的治疗结局,共纳入24项临床试验和19项真实世界研究。临床试验中来那度胺难治队列的中位无进展生存期和总生存期均短于意向治疗人群,真实世界研究报告的无进展生存期、总生存期和客观缓解率存在较大差异,提示该人群治疗结局欠佳。
要点
- 临床试验中来那度胺难治队列中位无进展生存期为8.8个月(n=2699),短于意向治疗人群的13.8个月(n=5380)。
- 临床试验中来那度胺难治队列中位总生存期为21.7个月(n=1066),短于意向治疗人群的35.9个月(n=2264)。
- 临床试验中来那度胺难治患者(n=2142)的群体加权平均客观缓解率为56.0%。
核心结论
- 临床试验与真实世界证据均显示来那度胺难治性复发/难治多发性骨髓瘤患者的治疗结局欠佳,凸显改善该人群治疗选择的需求。
研究设计与样本
- 系统性文献综述,检索2008年1月至2023年10月发表于英文文献的临床试验与真实世界研究,检索数据库包括Medline、EMBASE及其他电子数据库。
- 纳入24项临床试验和19项真实世界研究,对象为既往接受≥1线治疗、疾病进展且来那度胺难治的复发/难治多发性骨髓瘤成人患者。
- 主要结局包括无进展生存期、总生存期和总缓解率/客观缓解率。
主要发现
- 临床试验中来那度胺难治队列的群体加权中位无进展生存期为8.8个月(n=2699),意向治疗人群为13.8个月(n=5380)。
- 临床试验中来那度胺难治队列的群体加权中位总生存期为21.7个月(n=1066),意向治疗人群为35.9个月(n=2264)。
- 临床试验中来那度胺难治患者(n=2142)的群体加权平均客观缓解率为56.0%。
- 真实世界研究报告的无进展生存期(7项研究)、总生存期(8项研究)和客观缓解率(8项研究)存在较大差异。
- 真实世界研究中,来那度胺/硼替佐米难治患者的中位无进展生存期(5.5/5.5个月;n=81/n=25)低于来那度胺难治患者(7.3/8.0个月;n=81/n=61)(2项研究)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The growing use of frontline lenalidomide treatment in multiple myeloma (MM) is increasing the proportion of lenalidomide-refractory patients, which may limit the efficacy of subsequent lines of treatment (LOT). This systematic literature review (January 2008-October 2023) of clinical trials (CT) and real-world studies (RW) assessed treatment outcomes in adults with relapsed/refractory MM (RRMM) who were previously treated with ≥1 LOT, progressed and were lenalidomide-refractory. Medline, EMBASE and additional electronic databases were searched for articles published in English. Primary outcomes included progression-free survival (PFS), overall survival (OS) and overall/objective response rate (ORR); 24 CT and 19 RW were included. For CT, the population-weighted mean of median PFS (CT = 14) and OS (CT = 6) were shorter in the lenalidomide-refractory cohort (months: 8.8 [n = 2699] and 21.7 [n = 1066], respectively) than the intent-to-treat population (months: 13.8 [n = 5380] and 35.9 [n = 2264], respectively); the population-weighted (N = 2142) mean ORR for lenalidomide-refractory patients (CT = 18) was 56.0%. RW reported considerable variation in PFS (RW = 7), OS (RW = 8) and ORR (RW = 8); and median PFS (RW = 2; months) was lower in lenalidomide/bortezomib-refractory (5.5/5.5; n = 81/n = 25) versus lenalidomide-refractory (7.3/8.0; n = 81/n = 61) patients. These data provide evidence that clinical trials and real-world outcomes are suboptimal in lenalidomide-refractory patients with RRMM, highlighting the need to improve treatment options for this population.
引用
- Hartley-Brown MA, Weisel K, Bitetti J, et al. Multiple myeloma refractory to lenalidomide: A systematic literature review of trials and real-world evidence. Br J Haematol. 2024. PMID: 39031440. doi:10.1111/bjh.19627
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。